PPT-New Perspectives in Treatment Strategies for Follicular Lymphoma

Introduction Standard Frontline Therapy for FL GALLIUM Trial Phase 3Rituximab vs Obinutuzumab GALLIUM Trial PFS GALLIUM Trial Safety GALLIUM Trial Responses RELEVANCE Trial Phase 1 Rituximab Lenalidomide and Ibrutinib in Untreated FL. Agents . for . Indolent . L. ymphoma . and . Mantle Cell Lymphoma. . Stephen Ansell, MD, PhD. Mayo Clinic. Tiacci. et al, Nature . Reviews Cancer 6, 437-. 448, 2006.. Would we expect mantle cell lymphoma and follicular lymphoma to respond to similar agents?. Contemporary Treatment Strategies and Optimal Sequencing. Educational Objectives. After completing this program, participants should be able to:. Summarize the incidence and patient demographics of indolent B-cell . Contemporary Treatment Strategies and Optimal Sequencing. Educational Objectives. After completing this program, participants should be able to:. Summarize the incidence and patient demographics of indolent B-cell NHL (Non-Hodgkin Lymphoma), including prognostic factors that aid in accurate diagnosis and guide treatment decisions . nanoparticles. and. . microcontainers. . ex vivo . and . in vivo. Sergey. . Zaitsev. 1. , . Natalia. . Ksenofontova. 1. , . Yulia. . I. . Svenskaya. 1. , . . Olga. . Guslyakova. 1. , Elina . and their . precursor . cells. .  The name often refers to just the . cancerous. . ones . rather than all such . tumors. .. Many lymphomas are known to be due to specific genetic mutations.. 3. rd. ymphoma. Sobia Ozair. March 8, 2017. MD Anderson Lecture Series. Indolent NHL include:. Follicular. CLL/SLL. Marginal . zone. Cutaneous T-cell. Anaplastic Large Cell . Lymphoma. Follicular NHL. Most . Lisbon 2018. #EBMT18. Tuesday 20 . March. . 2018. , . 07:00-09:00 –Room 3B. EBMT LWP Open Research Forum. Tuesday 20 March 2018,.  . 11:00-12:30 . - . Auditorium II. Lymphoma Working Party Session. Sima Jeha, MD This is a controlled document and therefore must not be changed or photocopied L.13 High dose METHOTREXATE (high grade NHL CNS prophylaxis) Authorised by Lymphoma lead Dr. Graham Collins Date: M C76.4 Upper limb C76.5 Lower limb C76.7 Other ill-defined sites C76.8 Overlapping lesion of other and ill-defined sites C77.0 Lymph nodes of head, face and neck Supraclavicular lymph nodes C77.1 Helpline: 800 500 9976 | helpline@lymphoma.org Understanding LymphomaDiffuse Large B-Cell Lymphoma: Relapsed/Refractory Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin l a guide for patients - Information based on ESMO Clinical Practice Guidelines – v.201 4 .1 Page 1 This document is provided by the Anticancer Fund with the permission of ESMO. The information in Overview Case 3 • 59 year old man with lymphadenopathy in the neck, supraclavicular area, inguinal area . He states that he has had LN for at least 18 months and they have waxed and waned . Prof. . Alexey V. Danilov, MD, PhD,. 1. Dr. Massimo . Magagnoli. , MD,. 2 . Dr. Matthew J. . Matasar. , MD. 3. . SELECTED HIGHLIGHTS. 1. City of Hope National Medical Center, Duarte, CA, USA; . 2. Humanitas Cancer Center, .